23-301 Phase I
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
8 results
21-329 Phase II
A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors
23-392 Phase I
A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2
20-741 Phase II
A PHASE 1B/2 , STUDY OF AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB-S6-500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
23-423 Phase I
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers
22-571 Phase I
A phase I/Ib, open-label, multi-center, study of QEQ278 in patients with advanced solid tumors
20-236 Phase I
An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
22-062 Phase II
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 ß/¿ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies
Showing 1 - 10 of 8 results